Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Alnylam Pharmaceuticals, Inc. or IQVIA Holdings Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Latest Biotechnology and Alnylam Pharmaceuticals, Inc., IQVIA Holdings Inc. Stock News

As of July 30, 2026, Alnylam Pharmaceuticals, Inc. had a $27.4 billion market capitalization, compared to the Biotechnology median of $251.9 million. Alnylam Pharmaceuticals, Inc.’s stock is down 48.3% in 2026, down 24.4% in the previous five trading days and down 37.84% in the past year.

Currently, Alnylam Pharmaceuticals, Inc.’s price-earnings ratio is 52.0. Alnylam Pharmaceuticals, Inc.’s trailing 12-month revenue is $4.3 billion with a 12.5% net profit margin. Year-over-year quarterly sales growth most recently was 96.4%. Analysts expect adjusted earnings to reach $8.971 per share for the current fiscal year. Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.

As of July 30, 2026, IQVIA Holdings Inc. had a $39.1 billion market cap, putting it in the 92nd percentile of all stocks. IQVIA Holdings Inc.’s stock is up 4.3% in 2026, up 13% in the previous five trading days and up 22.23% in the past year.

Currently, IQVIA Holdings Inc.’s price-earnings ratio is 29.4. IQVIA Holdings Inc.’s trailing 12-month revenue is $17.0 billion with a 8.1% net profit margin. Year-over-year quarterly sales growth most recently was 8.7%. Analysts expect adjusted earnings to reach $12.959 per share for the current fiscal year. IQVIA Holdings Inc. does not currently pay a dividend.

How We Compare Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc. Growth Grades

Company	Ticker	Growth
Alnylam Pharmaceuticals, Inc.	ALNY	D
IQVIA Holdings Inc.	IQV	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Alnylam Pharmaceuticals, Inc. has a Growth Score of 32, which is Weak. IQVIA Holdings Inc. has a Growth Score of 100, which is Very Strong.

The Growth Grade Winner: IQVIA Holdings Inc.

As you can clearly see from the Growth Grade breakdown above, IQVIA Holdings Inc. has a more attractive growth grade than Alnylam Pharmaceuticals, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, IQVIA Holdings Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc.’s Quality Grades

Company	Ticker	Quality
Alnylam Pharmaceuticals, Inc.	ALNY	A
IQVIA Holdings Inc.	IQV	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Alnylam Pharmaceuticals, Inc. has a Quality Score of 83, which is Very Strong. IQVIA Holdings Inc. has a Quality Score of 63, which is Strong.

The Quality Grade Winner: Alnylam Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Alnylam Pharmaceuticals, Inc. has a better overall quality grade than IQVIA Holdings Inc.. For investors who are looking for companies with higher quality than others in the same industry, Alnylam Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Alnylam Pharmaceuticals, Inc.	ALNY	D
IQVIA Holdings Inc.	IQV	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Alnylam Pharmaceuticals, Inc. has a Earnings Estimate Score of 31, which is Negative. IQVIA Holdings Inc. has a Earnings Estimate Score of 71, which is Positive.

The Earnings Estimate Revisions Grade Winner: IQVIA Holdings Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, IQVIA Holdings Inc. has a better Earnings Estimate Revisions Grade than Alnylam Pharmaceuticals, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, IQVIA Holdings Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc. Grades

In addition to Growth, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Alnylam Pharmaceuticals, Inc. or IQVIA Holdings Inc. Stock?

Overall, Alnylam Pharmaceuticals, Inc. stock has a Growth Score of 32, Estimate Revisions Score of 31 and Quality Score of 83.

IQVIA Holdings Inc. stock has a Growth Score of 100, Estimate Revisions Score of 71 and Quality Score of 63.

Comparing Alnylam Pharmaceuticals, Inc. and IQVIA Holdings Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.